Table 3.
Baseline Demographic and Clinical Characteristics of the TRACER Trial Patients With Hemorrhagic Versus Nonhemorrhagic Stroke Overall
| Variable | Patients With Hemorrhagic Stroke (N=28) | Patients With Nonhemorrhagic Stroke (N=167) |
|---|---|---|
| Patient characteristics | ||
| Age, y | 70 (62–76) | 68 (60–73) |
| Female sex | 11 (39.3) | 42 (25.1) |
| Race | ||
| White | 24 (85.7) | 138 (83.1) |
| Black or African American | 0 (0.0) | 7 (4.2) |
| Asian | 1 (3.6) | 13 (7.8) |
| Native Hawaiian or other Pacific Islander | 0 (0.0) | 0 (0.0) |
| Multiracial | 3 (10.7) | 7 (4.2) |
| Body mass index, kg/m2 | 29 (25–31) | 27 (25–32)a |
| Region of enrollment | ||
| North America | 6 (21.4) | 58 (34.7) |
| Latin America | 4 (14.3) | 20 (12.0) |
| Europe 1 | 14 (50.0) | 65 (38.9) |
| Europe 2 | 3 (10.7) | 12 (7.2) |
| Asia/Pacific | 1 (3.6) | 10 (6.0) |
| Australia/New Zealand | 0 (0.0) | 2 (1.2) |
| Cardiovascular risk factors | ||
| Hypertension | 19 (67.9) | 138 (82.6) |
| Hypercholesterolemia | 14 (50.0) | 104 (62.3) |
| Diabetes mellitus | 11 (39.3) | 65 (38.9) |
| Smoker at enrollment | 3 (10.7) | 41 (24.6) |
| Comorbidities | ||
| Stroke | 1 (3.6) | 21 (12.6) |
| History of TIA | 3 (10.7) | 14 (8.4) |
| Myocardial infarction | 9 (32.1) | 54 (32.3) |
| Peripheral arterial vascular disease | 2 (7.1) | 22 (13.2) |
| History of atrial fibrillation | 2 (7.1) | 17 (10.2) |
| Status at time of presentation | ||
| Killip class ≤2 at enrollment | 27 (96.4) | 158 (95.2) |
| Creatinine clearance, mL/minb | 82 (60–102) | 82 (65–105) |
| ECG findings | ||
| ST‐segment elevation at enrollment | 1 (3.6) | 10 (6.0) |
| ST‐segment depression at enrollment | 11 (39.3) | 57 (34.1) |
Data are presented as median (quartile 1–quartile 3) for continuous variables and number (percentage) for discrete variables. TIA indicates transient ischemic attack; TRACER, Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.
a
For body mass index, N=165 for patients with nonhemorrhagic stroke.
b
For creatinine clearance, N=27 for patients with hemorrhagic stroke and N=154 for patients with nonhemorrhagic stroke.